Trump tariffs pharmaceuticals, exempting companies with US sites, aim to boost domestic production and impact global market dynamics.
Author: PharmaSignal News Desk
GSK CEO Luke Miels is set to lead the company into a pivotal growth phase starting January 2026.
Crystalys gout drug debuts with $205M funding and partial rights in multiple Asian countries.
Genmab Merus acquisition for $8 billion enhances its oncology portfolio with innovative therapies like Petosemtamab.
Bristol Myers Squibb launches Sotyktu at an 86% discount, reducing the price to $950 for cash-paying U.S. patients.
Trump drug price deadline prompts pharma firms to announce initiatives, impacting U.S. market with new models.
Glenmark Hengrui licensing deal secures $1 billion, granting exclusive rights and impacting the pharmaceutical market.
Successful drug launches need realistic forecasts and market preparation, says Jason O’Neill, highlighting common pitfalls in new product launches.
GSK CEO transition sees Emma Walmsley stepping down, with Luke Miels set to take over on 1 January 2026.
Cipla Q1 earnings beat forecast, leading to a 5% share increase on 10 September 2025.